Document is current
Any future updates will be listed below
-
Authors
Alonso-Valenteen, Felix
Mikhael, Simoun
Wang, HongQiang
Sims, Jessica
Taguiam, Michael
Teh, James
Sances, Sam
Wong, Michelle
Miao, Tianxin
Srinivas, Dustin
Gonzalez-Almeyda, Nelyda
Cho, Ryan H.
Sanchez, Romny
Nguyenle, Kimngan
Serrano, Erik
Ondatje, Briana
Benhaghnazar, Rebecca L.
Gray, Harry B.
Gross, Zeev
Yu, John
Svendsen, Clive N.
Abrol, Ravinder
Medina-Kauwe, Lali K. https://orcid.org/0000-0002-9807-5523
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA270324, R01 CA258204)
U.S. Department of Health & Human Services | National Institutes of Health (T32 HL134637, UG3NS105703, T32 HL134637, UG3NS105703, UG3NS105703)
U.S. Department of Defense (W81XWH-22-1-0953, W81XWH1910592, W81XWH-15-1-0604, W81XWH1910592)
- License Information
-
More Information
Article History
Received: 3 December 2021
Accepted: 14 January 2025
First Online: 21 February 2025
Competing interests
: The corresponding author L.K.M.-K. declares the following competing interests: US patents on HerDox technology, methods and uses (9078927, 9789201, 9850293, 10391180); targeted corrole technology, methods and uses (9757386); and delivery across the BBB and uses for targeting brain-localized/brain-metastatic tumours (10183078).
